Zhongzhu holding's acquisition of xintaidayi in a new anticancer drug recombinant human endostatin adenovirus injection

Zhongzhu holding, which has been suspended for three weeks, announced on the evening of January 23 that it intends to acquire 70% of the equity of Guangzhou new TEDA Biotechnology Co., Ltd., as well as a patent for anti-cancer gene therapy drugs, achievements of drug projects and future industrialization income to be obtained by new TEDA According to the disclosure, in order to obtain the new drug certificate, drug registration approval and future pharmaceutical industrialization income of "recombinant human endostatin adenovirus injection" biological drugs, Zhongzhu holding intends to sign the equity transfer agreement with natural person Huang Wenlin, to acquire 70% of its shares in Xintaida company, and "a kind of human vascular endothelial cell growth" to be owned by Xintaida company "Recombinant virus of inhibitor" patent, relevant achievements of drug project and future industrialization income The transaction is based on the patent and drug project transfer agreement signed by Guangzhou Dabo Biological Products Co., Ltd According to the agreement, Guangzhou Dabo will transfer all the expected benefits such as the summary results of all clinical trials of the above-mentioned patent rights and the new drug "recombinant human endostatin adenovirus injection" and the new drug certificate and drug registration approval that may be obtained in the future to Xintaida company The two companies are related companies, with Huang Wenlin holding 83.35% of the shares of Guangzhou Dabo The new drug "recombinant human endostatin adenovirus injection" involved in the acquisition of Zhongzhu Holding Co., Ltd is a national class I new drug In 2010, it won the gold medal of the 10th China invention patent and has full independent intellectual property rights It belongs to biomedical anti-cancer gene therapy drug According to the announcement, the new drug has completed phase I and phase II clinical trials, and has obtained phase III clinical approval from the State Food and drug administration, and is currently in clinical trials as planned The subjects of the new drug were located in the head and neck squamous cell carcinoma patients after second-line treatment, who could not be operated, abandoned or nasopharynx According to the equity transfer agreement, Zhongzhu holdings needs to pay RMB 10.5 million in installments for the 70% equity transfer of new Teda Company held by Huang Wenlin, and increase the capital of new TEDA in installments and fulfill the payment obligations of new TEDA to Guangzhou Dabo intangible assets, with the payment amount of RMB 150.5 million.